Figure 2.

A modified Pouchitis Disease Activity Index (mPDAI) <10 is associated with sustained clinical response to infliximab at a median follow-up of 48 weeks (p < 0.01). Clinical response was recorded as an improvement without return to baseline frequency, or return to baseline with persistent inflammation at endoscopy and mPDAI improvement of ≥2; complete response was judged as mPDAI <5 and return to baseline, and fistulae showing marked reduction in drainage with or without improvement on imaging.